Nata a Pistoia, 11/06/1980
Curriculum Vitae Informazioni personali Dr. Valentina Berti, M.D. Ph.D.Indirizzo Via Largo Brambilla, 3 FirenzeE-mail valentina.berti@unifi.it Nazionalità Italiana Istruzione e Formazione Laurea Laurea in Medicina e Chirurgia conseguita presso l’Università degli Studi di Firenze, Facoltà di Medicina e Chirurgia.Data: 21 Luglio 2005; Votazione: 110/110 con lodeTitolo della tesi: “Quantificazione dei recettori del sistema dopaminergico: studio SPECT con 123I-FP-CIT” Tirocinio post-laurea Novembre 2005 - Dicembre 2005Medicina Generale (Dr. Daniele Francini, M.D.) Dicembre 2005 - Gennaio 2006Medicina Interna (Prof. Loredana Poggesi, M.D.)Gennaio 2006 - Febbraio 2006Chirurgia Generale (Prof. Paolo Bechi, M.D.) Abilitazione all’esercizio della professione medica 15 Febbraio 2006 Scuola di Specializzazione Specializzazione in Medicina Nucleare conseguita presso la Scuola di Specializzazione in Medicina Nucleare, Università degli Studi di Firenze, Facoltà di Medicina e Chirurgia, Dipartimento di Fisiopatologia Clinica, Prof. Alberto Pupi - Prof. Roberto SciagràData: 30 Ottobre 2009Votazione: 70/70 con lodeTitolo della tesi: “La PET come endofenotipo nella malattia di Alzheimer: il successo dell’unione fra PET e genetica”Dottorato di Ricerca Dottorato di Ricerca in Neuroscienze, Scuola di Neuroscienze, Università degli Studi di Firenze. Data esame: 27/02/2013. Titolo Studio: “Neuroimaging studies in subjects at genetic risk of developing Alzheimer’s disease: the role of neuroimaging as endophenotype” Esperienza lavorativa Maggio 2006 – Agosto 2006 Medico del Servizio di Continuità Assistenziale per un totale di 500 ore. Novembre 2005 – Ottobre 2009 Medico Specializzando presso la Scuola di Specializzazione in Medicina Nucleare, Dipartimento di Fisiopatologia Clinica (Prof. Pupi - Prof. Sciagrà) Gennaio 2009 – Dicembre 2009 Ricercatore presso Center for Brain Health, New York University Medical Center, Prof. Mony de Leon, Supervisor: Dr. Lisa Mosconi Gennaio 2010 – Dicembre 2012 Dottorando iscritta alla Scuola di Dottorato in Neuroscienze (ciclo XXV), Università degli Studi di FirenzeAprile 2013 – Agosto 2013 Contratto co.co.co con Azienda Ospedaliero-Universitaria Careggi, nell’ambito del progetto GR-2009-1605077, titolo “Valutazione dosimetrica e metodologica del tracciante PET per amiloide 18F-FDDNP” PI: Valentina Berti. Settembre 2013 – Ottobre 2019 Ricercatore a Tempo Determinato (a e b), in regime di tempo pieno, presso il Dipartimento di Scienze Biomediche Sperimentali e Cliniche, Università degli Studi di Firenze, settore scientifico-disciplinare: MED 36, in afferenza assistenziale presso Azienda Ospedaliero-Universitaria Careggi, SOD Medicina Nucleare.
Da Novembre 2019 Professore Associato presso il Dipartimento di Scienze Biomediche Sperimentali e Cliniche, Università degli Studi di Firenze, settore scientifico-disciplinare: MED 36, in afferenza assistenziale presso Azienda Ospedaliero-Universitaria Careggi, SOD Medicina Nucleare Febbraio 2014 Abilitazione Scientifica Nazionale alle funzioni di Professore di seconda fascia nel settore concorsuale 06/I1 “Diagnostica per immagini, Radioterapia e Neuroradiologia” Attività di docenza Docente nel settore scientifico-disciplinare MED36 nella Scuola di Scienze della Salute Umana: Scuola di Specializzazione in Medicina Nucleare Corso di Laurea Tecniche di Radiologia Medica, per Immagini e Radioterapia, Insegnamento Radiofarmaci e Cinetica dei Mezzi di Contrasto, Modulo RadiofarmaciCorso di Laurea in Fisioterapia, Insegnamento Legislazione e Management in Area Sanitaria, Modulo Nozioni di RadioprotezioneCorso di Laurea in Ostetricia, Insegnamento Promozione della Salute e della Sicurezza, Modulo Diagnostica per ImmaginiCorso di Laurea in Infermieristica, Insegnamento Percorsi Diagnostico Terapeutico Assistenziali, Modulo Diagnostica per Immagini Master TSRM in Radioterapia, Diagnostica PET in Oncologia Partecipazioni a trials clinici in qualità di sperimentatore • Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU)• Effect of passive immunization on the progression of mild Alzheimer’s disease: Solanezumab vs placebo (H8-MC-LZAX), sponsor: Eli Lilly• A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer’s Disease Dementia (The DAYBREAK Study), sponsor: Eli Lilly)• A multicenter, phase III, randomized study to evaluate the efficacy of a response-adapted strategy to define maintenance after standard chemoimmunotherapy in patients with advanced-stage Follicular Lymphoma (FOLL12)• Studio di sicurezza post-autorizzazione per valutare l’efficacia del programma di formazione per valutatori Vizamyl in Europa, sponsor Ge Helathcare, Sperimentatore Principale• A multicenter, randomized, double-blind, active-controlled study to evaluate the effects of LCZ696 compared to valsartan on cognitive function in patients with chronic heart failure with preserved ejection fraction, sponsor: Novartis• Studio osservazionale prospettico volto a valutare l’efficacia del corso di formazione e delle misure di minimizzazione dei rischi raccomandate per l’uso del tracciante per uso diagnostico NeuraCeqTM nella pratica clinica post-autorizzazione: Studio sulla sicurezza post-autorizzazione (Post-Authorisation Safety Study, PASS), sponsor: Piramal
Progetti Finanziati Ministero della Salute, Bando Giovani Ricercatori 2009, GR-2009-1605077, titolo “Valutazione dosimetrica e metodologica del tracciante PET per amiloide 18F-FDDNP” PI: Valentina Berti.Ministero della Saute, Bando Giovani Ricercatori 2011, codice RF-2011-02347190, titolo: "Clinical genetic and neuroimaging profiles in Italian patients with Fronto-Temporal Dementia" PI: Silvia Bagnoli, Resonsabile unità neuroimaging: Valentina Berti.
• Bando AIFA “Interceptor Project”• • Bando Ricerca Finalizzata Ministero della Salute, “Development of operational research diagnostic criteria for diagnosis of Alzheimer's disease in the preclinical/predementia phase and implementation of SOPs for imaging and CSF biomarkers in Memory Clinics. An integrated care pathway for early diagnosis and best management in the National Health Service of five Italian regions.”, Progetto di Rete
Università degli Studi di Firenze, Bando anno 2016 per progetti competitivi per Ricercatori a Tempo Determinato, titolo: “MicroPET and microMRI for anti-VEGF response assessment in a murine model of human tumor as a future clinical imaging tool”, PI: Valentina Berti. Capacità e competenze personali Prima lingua ItalianoAltre lingue Inglese: fluente Capacità e competenze tecniche Trainer per la lettura delle immagini PET con traccianti per amiloide dei radiofarmaci: Florbetaben, Florbetapir, FlutemetamolSistemi operativi Windows, Linux, Mac OS XSoftware Microsoft Office (e simili)Image J, Osirix, MRIcro (processing ed analisi delle immagini)MIPAV, Mango (visualizzazione e processing delle immagini, trattamento file DICOM, segmentazione ROI, coregistrazione e trasformazione, grafici, immagini 4D)SPSS, SPM Congressi Partecipazione e presentazioni a congressi Presentazioni di lavori scientifici condotti nel campo dell’Imaging neurologico ed oncologico ai congressi annuali di Society of Nuclear Medicine, European Association of Nuclear Medicine, Radiology Society of North America, SINDEM, International Workshop on PET in Lymphoma and Myeloma, Associazione Italiana di Medicina Nucleare. Premi a congress:Radiology Society of North America Annual Meeting 2012, CME Education Exhibit “Neuroendocrine Neoplasms of the Lung: Pathologic Classification and Spectrum of Molecular Imaging Findings”, Award “Cum Laude”
Invited Speaker Mente e Movimento, Early Detection, Cagliari 2010, “PET nuovi tracers: PIB-F derivati”
Corso di Medicina Nucleare in Neurologia, Pesaro 2010, “Sviluppo attuale delle connessioni fra genetica ed imaging PET nella malattia di Alzheimer”
Corso di Medicina Nucleare in Neurologia, Pesaro 2011, “Esperienze a confronto di analisi semi-quantitativa”
Convegno Associazione Italiana di Psicogeriatria, Firenze 2011, “Approccio diagnostico alla demenza: dalle evidenze scientifiche al mondo reale”
Corso di Medicina Nucleare in Neurologia, Pesaro 2012, “Novità cliniche e MN in tema di FTD”
Corso di Medicina Nucleare in Neurologia, Pesaro 2012, “FDG-PET e parkinsonismi”
Corso di Medicina Nucleare in Neurologia, Pesaro 2013, “Analisi Automatica degli Studi di Perfusione/Metabolismo: SPM”
XVI Annual Meeting, Tuscany Critical Care Group, Maggio 2013: “Clinical use of PET in head injury”
European Association of Nuclear Medicine Annual Meeting 2012, Philips workshop “Imaging and Diagnosis of Neurodegenerative Dementia with Philips Gemini TF: Clinical Experience in Florence”
Congresso Nazionale Associazione Italiana di Medicina Nucleare 2013, lecture “FDG_PET e parkinsonismi” Corso di Aggiornamento AIMN, Gruppo Italiano di Cardiologia Nucleare, Assisi 2013, “La quantizzazione del flusso in PET”
Corso di Medicina Nucleare in Neurologia, Pesaro 2014: “FDG-PET e parkinsonismi”
Corso Mind and Brain 2014, on the waves of SPM, Basal Ganglia and amyloid imaging, lettura: “SPM: quando utilizzarlo e parte teorica”
International conference on new therapies for dementia and parkinsonian syndromes, Firenze Settembre 2014: “Neuroimaging: new biomarkers for Alzheimer disease and Parkinson disease”
Congresso Gli orizzonti della Cardiologia Nucleare, Napoli Novembre 2014 e Pisa Gennaio 2015: “Parametri quantitativi nel referto di cardiologia nucleare. Devono essere sempre e comunque riportati? PET”
Congresso Nazionale Associazione Italiana di Medicina Nucleare 2015, lecture “Imaging quantitativo in Medicina Nucleare. Oltre l’immagine: verso la quantificazione assoluta in oncologia”
Corso “La Medicina Nucleare in Neurologia: Attualità e Prospettive”, Bolzano, Marzo 2015: “Disturbi del movimento: Ruolo del 123-I FP-CIT e del 18F-FDG”
Corso di Medicina Nucleare in Neurologia, Pesaro 2015, “Lettura di Studi di traccianti recettoriali: semeiotica medico-nucleare”
Congresso Associazione Italiana Psicogeriatria Ottobre 2015, “Visualizzare l’amiloide: basi biologiche e utilizzo clinico”
XVI Corso di Aggiornamento Gruppo Italiano di Medicina Nucleare, Novembre 2015: “It’s all in numbers - La quantizzazione in CN. La riserva coronarica: PET”
Corso GiovaNET, Montecatini Terme, Novembre 2015: “Presentazione e discussione di esperienza di pratica clinica quotidiana simulata 1”
European Conference on Clinical Neurosciences, Roma, 2016: “Clinical impact of PET and MRI in parkinsonism”
Corsi di Medicina Nucleare in Neurologia, organizzati dal Gruppo di Studio di Neurologia dell’Associazione Italiana di Medicina Nucleare negli anni 2016, 2017 e 2018, con i seguenti titoli: “Il paziente con ipometabolismo della corteccia associativa/limbica anteriore”, “Lettura di studi di traccianti recettoriali: semeiotica medico-nucleare” e “Novità in tema di imaging molecolare (FDG, amyPET, DAT, MIBG) nella diagnosi delle principali Malattie dementigene”
Congresso Nazionale Associazione Italiana di Medicina Nucleare 2017, lecture “I colpevoli delle demenze: dall’amiloide alla tau”
Congresso Nazionale Associazione Italiana di Medicina Nucleare 2019, con il titolo: “Neuroimaging Molecolare: la clinica oltre la ricerca”
Congresso Nazionale Fondazione Italiana Linfomi 2018, con il titolo: “Novità da Menton
International conference on new therapies for Parkinson's disease and dementia, 2019, con il titolo: “PET tracers: expectations, successes and pitfalls”
Palestra di Refertazione in Medicina Nucleare, 2018, CNR Pisa, con il titolo: “PET FDG e con traccianti per amiloide”
Convegno su PET cerebrale con traccianti per amiloide, Potenza 2017, con il titolo: “Florbetapir F-18: Tecniche di lettura e presentazione casi clinici”
Pubblicazioni 1. Berti V, Pupi A, Ramat S, Vanzi E, De Cristofaro MT, Pellicanò G, Mungai F, Marini P, Sorbi S.Clinical correlation of the binding potential with 123I-FP-CIT in de novo idiopathic Parkinson's disease patients.Eur J Nucl Med Mol Imaging. 2008; 35: 2220-6.
2. Osorio RS, Berti V, Mosconi L, Li Y, Glodzik L, De Santi S, De Leon MJ.Evaluation of early dementia (Mild cognitive impairment)PET Clinics. 2010; 5:15-31.
3. Berti V, Polito C, Ramat S, Vanzi E, De Cristofaro MT, Pellicanò G, Mungai F, Marini P, Formiconi AR, Sorbi S, Pupi A.Brain metabolic correlates of dopaminergic degeneration in de novo idiopathic Parkinson's disease. Eur J Nucl Med Mol Imaging. 2010; 37:537-44
4. Mosconi L, Berti V, Swerdlow RH, Pupi A, Duara R, de Leon MJ.Maternal transmission of Alzheimer’s disease: prodromal metabolic phenotype and the search for genes. Hum Genomics. 2010;4:170-93.
5. Mosconi L, Rinne JO, Tsui WH, Berti V, Li Y, Wang H, Murray J, Scheinin N, Någren K, Williams S, Glodzik L, De Santi S, Vallabhajosula S, de Leon MJ.Increased fibrillar amyloid-{beta} burden in normal individuals with a family history of late-onset Alzheimer's.Proc Natl Acad Sci U S A. 2010 Mar 30;107(13):5949-54.
6. Mosconi L, Berti V, Glodzik L, Pupi A, De Santi S, de Leon MJ.Pre-Clinical Detection of Alzheimer's Disease Using FDG-PET, with or without Amyloid Imaging.J Alzheimers Dis. 2010;20(3):843-54.
7. Berti V, Osorio RS, Mosconi L, Li Y, De Santi S, de Leon MJ.Early detection of Alzheimer’s disease with PET imaging. Neurodeg Dis, 2010; 7:131-135.
8. Sciagrà R, Berti V, Genovese S, Pupi A.Reliability of myocardial perfusion gated SPECT for the reproducible evaluation of resting left ventricular functional parameters in long-term follow-up.Eur J Nucl Med Mol Imaging. 2010 Aug;37(9):1722-9.
9. Berti V, Nacmias B, Bagnoli S, Sorbi S.Alzheimer's disease: genetic basis and amyloid imaging as endophenotype.Q J Nucl Med Mol Imaging. 2011 Jun;55(3):225-36.
10. Berti V, Pupi A, Mosconi L.PET/CT in diagnosis of dementia.Ann N Y Acad Sci. 2011 Jun;1228(1):81-92.
11. Berti V, Pupi A, Mosconi L.PET/CT in diagnosis of movement disorders.Ann N Y Acad Sci. 2011 Jun;1228(1):93-108.
12. Berti V, Sciagrà R, Acampa W, Ricci F, Cerisano G, Gallicchio R, Vigorito C, Pupi A, Cuocolo A.Relationship between infarct size and severity measured by gated SPECT and long-term left ventricular remodelling after acute myocardial infarction.Eur J Nucl Med Mol Imaging. 2011 Jun;38(6):1124-31.
13. Berti V, Mosconi L, Glodzik L, Li Y, Murray J, De Santi S, Pupi A, Tsui W, De Leon MJ.Structural brain changes in normal individuals with a maternal history of Alzheimer's.Neurobiol Aging. 2011 Feb 12. [Epub ahead of print]
14. Mosconi L, Berti V, McHugh P, Pupi A, De Leon MJ.A tale of two tracers: Glucose metabolism and amyloid positron emission tomography imaging in Alzheimer’s disease.Advances in Alzheimer’s disease. 2011; 2:219-234.Handbook of imaging the Alzheimer Brain, IOS Press 15. Polito C, Berti V, Ramat S, Vanzi E, De Cristofaro MT, Pellicanò G, Mungai F, Marini P, Formiconi A, Sorbi S, Pupi A.Interaction of caudate dopamine depletion and brain metabolic changes with cognitive dysfunction in early Parkinson's disease.Neurobiol Aging. 2012; 1:206.e29-206.e39.
16. Berti V, Polito C, Borghammer P, Ramat S, Mosconi L, Vanzi E, De Cristofaro MT, De Leon M, Sorbi S, Pupi A.Alternative normalization methods demonstrate widespread cortical hypometabolism in untreated de novo Parkinson's disease.Q J Nucl Med Mol Imaging. 2012; 56:299-308.
17. Sciagrà R, Cipollini F, Berti V, Migliorini A, Antoniucci D, Pupi A. Detection of infarct size safety threshold for left ventricular ejection fraction impairment in acute myocardial infarction successfully treated with primary percutaneous coronary intervention. Eur J Nucl Med Mol Imaging. 2013; 40:542-547.
18. Mungai F, Berti V, Colagrande S. Bile leak after elective laparoscopic cholecystectomy: role of MR imaging. J Radiol Case Rep. 2013; 7:25-32.
19. Tomberli B, Cecchi F, Sciagrà R, Berti V, Lisi F, Torricelli F, Morrone A, Castelli G, Yacoub MH, Olivotto I.Coronary microvascular dysfunction is an early feature of cardiac involvement in patients with Anderson-Fabry disease.Eur J Heart Fail. 2013 Dec;15(12):1363-73
20. Nacmias B, Berti V, Piaceri I, Sorbi S. FDG PET and the genetics of dementiaClin Transl Imaging, 2013; 1:235-246.
21. Berti V, Vanzi E, Polito C, Pupi A.Back to the future: the absolute quantification of cerebral metabolic rate of glucose. Clin Transl Imaging, 2013; 1:289-296.
22. Berti V, Mosconi L, Pupi A.Brain: Normal Variations and Benign Findings in FDG PET/CT imaging. PET Clin. 2014 Apr;9(2):129-40.
23. Paganini M, Biggeri A, Romoli AM, Mechi C, Ghelli E, Berti V, Pradella S, Bucciantini S, Catelan D, Saccardi R, Lombardini L, Mascalchi M, Massacesi L, Porfirio B, Di Lorenzo N, Vannelli GB, Gallina P.Fetal striatal grafting slows motor and cognitive decline of Huntington's disease.J Neurol Neurosurg Psychiatry. 2014 Sep;85(9):974-81.
24. Gallina P, Paganini M, Biggeri A, Marini M, Romoli A, Sarchielli E, Berti V, Ghelli E, Guido C, Lombardini L, Mazzanti B, Simonelli P, Peri A, Maggi M, Porfirio B, Di Lorenzo N, Vannelli GB.Human Striatum Remodelling after Neurotransplantation in Huntington's Disease.Stereotact Funct Neurosurg. 2014 Jul 30;92(4):211-217.
25. Laparoscopic Splenectomy as Quaternary Cytoreduction for Isolated Parenchymal Splenic Recurrence of Epitelial Tubo-Ovarian Cancer: Report of a Case and Literature Review.Sorbi F, Prosperi P, Villanucci A, Berti V, Sisti G, Fambrini M.Gynecol Obstet Invest. 2015;80(4):265-71.
26. Nutrient patterns and brain biomarkers of Alzheimer's disease in cognitively normal individuals.Berti V, Murray J, Davies M, Spector N, Tsui WH, Li Y, Williams S, Pirraglia E, Vallabhajosula S, McHugh P, Pupi A, de Leon MJ, Mosconi L.J Nutr Health Aging. 2015 Apr;19(4):413-23. doi: 10.1007/s12603-014-0534-0.
27. Rethinking on the concept of biomarkers in preclinical Alzheimer's disease.Berti V, Polito C, Lombardi G, Ferrari C, Sorbi S, Pupi A.Neurol Sci. 2016 May;37(5):663-72.
28. Segmental quantitative myocardial perfusion with PET for the detection of significant coronary artery disease in patients with stable angina.Berti V, Sciagrà R, Neglia D, Pietilä M, Scholte AJ, Nekolla S, Rouzet F, Pupi A, Knuuti J.Eur J Nucl Med Mol Imaging. 2016 Jul;43(8):1522-9.
29. Cerebral metabolic rate of glucose quantification with the aortic image-derived input function and Patlak method: numerical and patient data evaluation.Vanzi E, Berti V, Polito C, Freddi I, Comis G, Rubello D, Sorbi S, Pupi A.Nucl Med Commun. 2016 Apr 7. [Epub ahead of print]
30. Role of quantitative myocardial positron emission tomography for risk stratification in patients with hypertrophic cardiomyopathy: a 2016 reappraisal.Castagnoli H, Ferrantini C, Coppini R, Passeri A, Baldini K, Berti V, Cecchi F, Olivotto I, Sciagrà R.Eur J Nucl Med Mol Imaging. 2016 Dec;43(13):2413-2422.
31. Low Florbetapir PET Uptake and Normal Aβ1 - 42 Cerebrospinal Fluid in an APP Ala 713Thr Mutation Carrier.Lombardi G, Berti V, Tedde A, Bagnoli S, Piaceri I, Polito C, Lucidi G, Ferrari C, Ginestroni A, Moretti M, Pupi A, Nacmias B, Sorbi S.J Alzheimers Dis. 2017 Mar 10. doi: 10.3233/JAD-161170.
32. Sex differences in Alzheimer risk: Brain imaging of endocrine vs chronologic aging.Mosconi L, Berti V, Quinn C, McHugh P, Petrongolo G, Varsavsky I, Osorio RS, Pupi A, Vallabhajosula S, Isaacson RS, de Leon MJ, Brinton RD.Neurology. 2017 Aug 30. doi: 10.1212/WNL.0000000000004425. [Epub ahead of print]
33. Perimenopause and emergence of an Alzheimer's bioenergetic phenotype in brain and periphery.Mosconi L, Berti V, Guyara-Quinn C, McHugh P, Petrongolo G, Osorio RS, Connaughty C, Pupi A, Vallabhajosula S, Isaacson RS, de Leon MJ, Swerdlow RH, Brinton RD.PLoS One. 2017 Oct 10;12(10):e0185926.
34. Association of the New Variant Tyr424Asp at TBK1 Gene with Amyotrophic Lateral Sclerosis and Cognitive Decline.Piaceri I, Bessi V, Matà S, Polito C, Tedde A, Berti V, Bagnoli S, Braccia A, Del Mastio M, Pignone AM, Pupi A, Sorbi S, Nacmias B.J Alzheimers Dis. 2018;61(1):41-46.
35. Alzheimer's Disease Progression: Factors Influencing Cognitive Decline.Ferrari C, Lombardi G, Polito C, Lucidi G, Bagnoli S, Piaceri I, Nacmias B, Berti V, Rizzuto D, Fratiglioni L, Sorbi S.J Alzheimers Dis. 2018;61(2):785-791.
36. Diffusion-Weighted and Perfusion-Weighted MRI to Evaluate Therapeutic Response in Lymphoma: A Comparison with FDG-PET/CT.Calistri L, Puccini B, Berti V, Grazzini G, Nardi C, Rigacci L, Colagrande S.Acta Haematol. 2018;139(2):74-76.
37. Biomarkers study in atypical dementia: proof of a diagnostic work-up. Lombardi G, Polito C, Berti V, Ferrari C, Lucidi G, Bagnoli S, Piaceri I, Nacmias B, Pupi A, Sorbi S. Neurol Sci. 2018 Jul;39(7):1203-1210. doi: 10.1007/s10072-018-3400-8.
38. Mediterranean diet and 3-year Alzheimer brain biomarker changes in middle-aged adults. Berti V, Walters M, Sterling J, Quinn CG, Logue M, Andrews R, Matthews DC, Osorio RS, Pupi A, Vallabhajosula S, Isaacson RS, de Leon MJ, Mosconi L. Neurology. 2018 May 15;90(20):e1789-e1798. doi: 10.1212/WNL.0000000000005527.
39. The use of Deauville 5-point score could reduce the risk of false-positive fluorodeoxyglucose-positron emission tomography in the posttherapy evaluation of patients with primary bone lymphomas. Rigacci L, Kovalchuk S, Berti V, Puccini B, Mannelli L, Benelli G, Dini C, Pupi A, Bosi A. World J Nucl Med. 2018 Jul-Sep;17(3):157-165. doi: 10.4103/wjnm.WJNM_42_17.
40. Crossed aphasia in nonfluent variant of primary progressive aphasia carrying a GRN mutation. Bessi V, Piaceri I, Padiglioni S, Bagnoli S, Berti V, Sorbi S, Nacmias B. J Neurol Sci. 2018 Sep 15;392:34-37. doi: 10.1016/j.jns.2018.06.026.
41. Contribution of Bilingualism to Cognitive Reserve of an Italian Literature Professor at High Risk for Alzheimer's Disease. Lombardi G, Polito C, Berti V, Bagnoli S, Nacmias B, Pupi A, Sorbi S. J Alzheimers Dis. 2018;66(4):1389-1395. doi: 10.3233/JAD-180736.
42. Characterization of functionally significant coronary artery disease by a coronary computed tomography angiography-based index: a comparison with positron emission tomography. Anagnostopoulos CD, Siogkas PK, Liga R, Benetos G, Maaniitty T, Sakellarios AI, Koutagiar I, Karakitsios I, Papafaklis MI, Berti V, Sciagrà R, Scholte AJHA, Michalis LK, Gaemperli O, Kaufmann PA, Pelosi G, Parodi O, Knuuti J, Fotiadis DI, Neglia D. Eur Heart J Cardiovasc Imaging. 2019 Jan 9. doi: 10.1093/ehjci/jey199.
43. Primary Progressive Aphasia: Natural History in an Italian Cohort. Ferrari C, Polito C, Vannucchi S, Piaceri I, Bagnoli S, Lombardi G, Lucidi G, Berti V, Nacmias B, Sorbi S. Alzheimer Dis Assoc Disord. 2019 Jan 10. doi: 10.1097/WAD.0000000000000282.
44. CT assessment of tumor heterogeneity and the potential for the prediction of human papillomavirus status in oropharyngeal squamous cell carcinoma. Mungai F, Verrone GB, Pietragalla M, Berti V, Addeo G, Desideri I, Bonasera L, Miele V. Radiol Med. 2019 Mar 25. doi: 10.1007/s11547-019-01028-6.
45. A Gene Expression-based Model to Predict Metabolic Response After Two Courses of ABVD in Hodgkin Lymphoma Patients.Luminari S, Donati B, Casali M, Valli R, Santi R, Puccini B, Kovalchuk S, Ruffini A, Fama A, Berti V, Fragliasso V, Zanelli M, Vergoni F, Versari A, Rigacci L, Merli F, Ciarrocchi A.Clin Cancer Res. 2020 Jan 15;26(2):373-383. doi: 10.1158/1078-0432.CCR-19-2356. Epub 2019 Oct 23.
46. Electronic processing of digital panoramic radiography for the detection of apical periodontitis.Nardi C, Calistri L, Pietragalla M, Vignoli C, Lorini C, Berti V, Mungai F, Colagrande S.Radiol Med. 2020 Feb;125(2):145-154. doi: 10.1007/s11547-019-01102-z.
47. A case of limbic encephalitis evolving into a frontotemporal dementia-like picture.Lombardi G, Matà S, Berti V, Padiglioni S, Ginestroni A, Piaceri I, Bagnoli S, Nacmias B, De Cristofaro MT, Pupi A, Sorbi S.Psychogeriatrics. 2020 May;20(3):355-357. doi: 10.1111/psyg.12503.
48. 99mTc-EDDA/HYNIC-TOC is a New Opportunity in Neuroendocrine Tumors of the Lung (and in other Malignant and Benign Pulmonary Diseases).Briganti V, Cuccurullo V, Berti V, Di Stasio GD, Linguanti F, Mungai F, Mansi L.Curr Radiopharm. 2020;13(3):166-176. doi: 10.2174/1874471013666191230143610.
49. Challenges in Alzheimer's Disease Diagnostic Work-Up: Amyloid Biomarker Incongruences.Lombardi G, Pupi A, Bessi V, Polito C, Padiglioni S, Ferrari C, Lucidi G, Berti V, De Cristofaro MT, Piaceri I, Bagnoli S, Nacmias B, Sorbi S.J Alzheimers Dis. 2020;77(1):203-217. doi: 10.3233/JAD-200119.
50. Aggressive Disease Course of Multiple Myeloma with Concomitant ALK-Negative Anaplastic Large Cell Lymphoma: A Case Report with an Unusual Presentation.Staderini M, Mannelli L, Antonioli E, Puccini B, Berti V, Mungai F, Vergoni F, Carrai V, Rigacci L, Bosi A.Case Rep Hematol. 2020 Jan 16;2020:6309736. doi: 10.1155/2020/6309736.
51. Diagnostic imaging of typical lung carcinoids: relationship between MDCT, 111In-Octreoscan and 18F-FDG-PET imaging features with Ki-67 index.Danti G, Berti V, Abenavoli E, Briganti V, Linguanti F, Mungai F, Pradella S, Miele V.Radiol Med. 2020 Aug;125(8):715-729. doi: 10.1007/s11547-020-01172-4.
52. Metastatic intracranial solitary fibrous tumors/hemangiopericytomas: description of two cases with radically different behaviors and review of the literature.Lavacchi D, Antonuzzo L, Briganti V, Berti V, Abenavoli EM, Linguanti F, Messerini L, Giaccone G.Anticancer Drugs. 2020 Jul;31(6):646-651. doi: 10.1097/CAD.0000000000000900.
53. Linguistic profiles, brain metabolic patterns and rates of amyloid-β biomarker positivity in patients with mixed primary progressive aphasia.Mazzeo S, Polito C, Padiglioni S, Berti V, Bagnoli S, Lombardi G, Piaceri I, Carraro M, De Cristofaro MT, Passeri A, Ferrari C, Nacmias B, Sorbi S, Bessi V.Neurobiol Aging. 2020 Dec;96:155-164. doi: 10.1016/j.neurobiolaging.2020.09.004. Epub 2020 Sep 8.
54. Neural correlates of naming errors across different neurodegenerative diseases: An FDG-PET study.Catricalà E, Polito C, Presotto L, Esposito V, Sala A, Conca F, Gasparri C, Berti V, Filippi M, Pupi A, Sorbi S, Iannaccone S, Magnani G, Cappa SF, Perani D.Neurology. 2020 Nov 17;95(20):e2816-e2830. doi: 10.1212/WNL.0000000000010967. Epub 2020 Oct 1.
55. Validation of FDG-PET datasets of normal controls for the extraction of SPM-based brain metabolism maps.Caminiti SP, Sala A, Presotto L, Chincarini A, Sestini S, Perani D; Alzheimer’s Disease Neuroimaging Initiative (ADNI), for the Associazione Italiana Medicina Nucleare (AIMN) datasets, The AIMN Neurology Study-Group collaborators:, Schillaci O, Berti V, Calcagni ML, Cistaro A, Morbelli S, Nobili F, Pappatà S, Volterrani D, Gobbo CL.Eur J Nucl Med Mol Imaging. 2021 Jan 10. doi: 10.1007/s00259-020-05175-1.
56. Matching Clinical Diagnosis and Amyloid Biomarkers in Alzheimer's Disease and Frontotemporal Dementia.Giacomucci G, Mazzeo S, Bagnoli S, Casini M, Padiglioni S, Polito C, Berti V, Balestrini J, Ferrari C, Lombardi G, Ingannato A, Sorbi S, Nacmias B, Bessi V.J Pers Med. 2021 Jan 14;11(1):47. doi: 10.3390/jpm11010047
57. Baseline metabolic tumor volume calculation using different SUV thresholding methods in Hodgkin lymphoma patients: interobserver agreement and reproducibility across software platforms.Tutino F, Puccini G, Linguanti F, Puccini B, Rigacci L, Kovalchuk S, Sciagrà R, Berti V.Nucl Med Commun. 2021 Mar 1;42(3):284-291. doi: 10.1097/MNM.0000000000001324.
58. Behavioural disorders in Alzheimer's disease: the descriptive and predictive role of brain 18 F-fluorodesoxyglucose-positron emission tomography.Cappelletto P, Polito C, Berti V, Lombardi G, Lucidi G, Bessi V, Sorbi S, Ferrari C.Psychogeriatrics. 2021 Apr 21. doi: 10.1111/psyg.12699.
59. Menopause impacts human brain structure, connectivity, energy metabolism, and amyloid-beta deposition.Mosconi L, Berti V, Dyke J, Schelbaum E, Jett S, Loughlin L, Jang G, Rahman A, Hristov H, Pahlajani S, Andrews R, Matthews D, Etingin O, Ganzer C, de Leon M, Isaacson R, Brinton RD.Sci Rep. 2021 Jun 9;11(1):10867. doi: 10.1038/s41598-021-90084-y.PMID: 34108509
60. Imaging biomarkers in the diagnosis of salivary gland tumors: the value of lesion/parenchyma ratio of perfusion-MR pharmacokinetic parameters.Mungai F, Verrone GB, Bonasera L, Bicci E, Pietragalla M, Nardi C, Berti V, Mazzoni LN, Miele V.Radiol Med. 2021 Oct;126(10):1345-1355. doi: 10.1007/s11547-021-01376-2. Epub 2021 Jun 28.PMID: 34181206 61. Evaluation of Age and Sex-Related Metabolic Changes in Healthy Subjects: An Italian Brain 18F-FDG PET Study.Allocca M, Linguanti F, Calcagni ML, Cistaro A, Gaudieri V, Guerra UP, Morbelli S, Nobili F, Pappatà S, Sestini S, Volterrani D, Berti V, For The Neurology Study Group Of The Italian Association Of Nuclear Medicine.J Clin Med. 2021 Oct 25;10(21):4932. doi: 10.3390/jcm10214932.PMID: 34768454
62. Cerebral amyloid load determination in a clinical setting: interpretation of amyloid biomarker discordances aided by tau and neurodegeneration measurements.Nerattini M, Rubino F, Arnone A, Polito C, Mazzeo S, Lombardi G, Puccini G, Nacmias B, De Cristofaro MT, Sorbi S, Pupi A, Sciagrà R, Bessi V, Berti V.Neurol Sci. 2021 Nov 5. doi: 10.1007/s10072-021-05704-2. Online ahead of print.PMID: 34739618
63. Gastrointestinal neuroendocrine neoplasms (GI-NENs): hot topics in morphological, functional, and prognostic imaging.Danti G, Flammia F, Matteuzzi B, Cozzi D, Berti V, Grazzini G, Pradella S, Recchia L, Brunese L, Miele V.Radiol Med. 2021 Dec;126(12):1497-1507. doi: 10.1007/s11547-021-01408-x. Epub 2021 Aug 24.PMID: 34427861
Partecipazione a numerosi trial clinici con traccianti per amiloide marcati con 18F
Legenda
Born in Pistoia, June 11th 1980
Curriculum Vitae
Personal information
Valentina Berti, M.D., Ph.D.
Address(es)
Department of Experimental and Clinical Biomedical Sciences “Mario Serio”, University of Florence, Viale Morgagni, 50 - 50134 Firenze (FI), Italy
Azienda Ospedaliero Universitaria Careggi, Largo Brambilla, 3 – 50134 Firenze (FI), Italy
E-mail
Nationality
italian
Date of birth
11 June 1980
Education and training
Degree in Medicine and Surgery at the University of Florence – Faculty of Medicine and Surgery
Date: 21st July 2005; with the final mark of 110/110 cum laude
Study title: “Dopaminergic system receptor quantification: SPECT study with 123I-FP-CIT”
Post-graduate internships:
November 2005 – December 2005
General Medicine (Dr. Daniele Francini, M.D.)
December 2005 – January 2006
Internal Medicine (Prof. Loredana Poggesi, M.D.)
January 2006 – February 2006
General Surgery (Prof. Paolo Bechi, M.D.)
Italian Medical License
15th February 2006 with the score of 265/270
Residency
Residency in Nuclear Medicine at the University of Florence, Clinical Pathophysiology Department, Prof. Alberto Pupi, Prof. Roberto Sciagrà
Date: 30th October 2009, with the final mark of 70/70 cum laude
Study title: “PET as an endophenotype in AD: the successful union of PET and genetics”
PhD
PhD in Neurosciences, School of Neurosciences, University of Florence (Prof. Massacesi), Tutor: Prof. Alberto Pupi.
Date: 27th February 2013, Study title: “Neuroimaging studies in subjects at genetic risk of developing Alzheimer’s disease: the role of neuroimaging as endophenotype”.
Work experience
May 2006 – August 2006
Covering Doctor for at least 500 hours
November 2005 – October 2009
Training doctor at the Nuclear Medicine Residency school (Chairman: Prof. Alberto Pupi) Department of Clinical Pathophysiology, Nuclear Medicine Section, University of Florence,
85, viale Morgagni, 50134, Florence, Italy
January 2009 – December 2009
Researcher at Center for Brain Health, New York University School of Medicine, Chairman: Prof. Mony de Leon, Supervisor: Dr. Lisa Mosconi
January 2010 – December 2012
PhD student in PhD School of Neurosciences, University of Florence
March 2013 – August 2013
Fixed-term contract of collaboration with Azienda Ospedaliero-Universitaria Careggi, Florence
September 2013 – October 2019
Full-time researcher at University of Florence, Department of Biomedical, Experimental and Clinical Sciences, Nuclear Medicine Unit
From November 2019
Associate Professor, University of Florence, Department of Biomedical, Experimental and Clinical Sciences, Nuclear Medicine Unit
Invited speaker at congresses
Grants Funded
Participation as Investigator in research projects
Supervision of Students
Since 2013: Supervision of Students of the School of Medicine during exercise in Nuclear Medicine.
Other collaborations
Participation in the creation of the spin-off "Imadrom", for the development of imaging techniques with molecular and functional tracers in clinical and preclinical research.
Personal skills and competences
Mother-language
Italian
Other language(s)
English: fluent
Publications
Clinical correlation of the binding potential with 123I-FP-CIT in de novo idiopathic Parkinson's disease patients.
Eur J Nucl Med Mol Imaging. 2008; 35: 2220-6.
IF: 4.532 Citations: 5
Evaluation of early dementia (Mild cognitive impairment)
PET Clinics. 2010; 5:15-31.
IF: 0.23 Citations: 0
Brain metabolic correlates of dopaminergic degeneration in de novo idiopathic Parkinson's disease.
Eur J Nucl Med Mol Imaging. 2010; 37:537-44
IF: 5.036 Citations: 7
Maternal transmission of Alzheimer’s disease: prodromal metabolic phenotype and the search for genes.
Hum Genomics. 2010;4:170-93.
IF: 2.25 Citations: 17
Increased fibrillar amyloid-{beta} burden in normal individuals with a family history of late-onset Alzheimer's.
Proc Natl Acad Sci U S A. 2010 Mar 30;107(13):5949-54.
IF: 9.771 Citations: 35
Pre-Clinical Detection of Alzheimer's Disease Using FDG-PET, with or without Amyloid Imaging.
J Alzheimers Dis. 2010;20(3):843-54.
IF: 4.261 Citations: 19
Early detection of Alzheimer’s disease with PET imaging.
Neurodeg Dis, 2010; 7:131-135.
IF: 3.791 Citations: 10
Reliability of myocardial perfusion gated SPECT for the reproducible evaluation of resting left ventricular functional parameters in long-term follow-up.
Eur J Nucl Med Mol Imaging. 2010 Aug;37(9):1722-9.
IF: 5.036 Citations: 4
Alzheimer's disease: genetic basis and amyloid imaging as endophenotype.
Q J Nucl Med Mol Imaging. 2011 Jun;55(3):225-36.
IF: 2.256 Citations: 2
PET/CT in diagnosis of dementia.
Ann N Y Acad Sci. 2011 Jun;1228(1):81-92.
IF: 3.155 Citations: 2
PET/CT in diagnosis of movement disorders.
Ann N Y Acad Sci. 2011 Jun;1228(1):93-108.
IF: 3.155 Citations: 0
Relationship between infarct size and severity measured by gated SPECT and long-term left ventricular remodelling after acute myocardial infarction.
Eur J Nucl Med Mol Imaging. 2011 Jun;38(6):1124-31.
Structural brain changes in normal individuals with a maternal history of Alzheimer's.
Neurobiol Aging. 2011 Dec;32(12):2325.e17-26.
A tale of two tracers: Glucose metabolism and amyloid positron emission tomography imaging in Alzheimer’s disease.
Advances in Alzheimer’s disease. 2011; 2:219-234.
Handbook of imaging the Alzheimer Brain, IOS Press
Interaction of caudate dopamine depletion and brain metabolic changes with cognitive dysfunction in early Parkinson's disease.
Neurobiol Aging. 2012; 1:206.e29-206.e39.
Alternative normalization methods demonstrate widespread cortical hypometabolism in untreated de novo Parkinson's disease.
Q J Nucl Med Mol Imaging. 2012; 56:299-308.
Detection of infarct size safety threshold for left ventricular ejection fraction impairment in acute myocardial infarction successfully treated with primary percutaneous coronary intervention.
Eur J Nucl Med Mol Imaging. 2013 Apr;40(4):542-7.
Bile leak after elective laparoscopic cholecystectomy: role of MR imaging.
J Radiol Case Rep. 2013 Jan;7(1):25-32.
Coronary microvascular dysfunction is an early feature of cardiac involvement in patients with Anderson-Fabry disease.
Eur J Heart Fail. 2013 Dec;15(12):1363-73.
FDG PET and the genetics of dementia
Clin Transl Imaging, 2013; 1:235-246.
Back to the future: the absolute quantification of cerebral metabolic rate of glucose.
Clin Transl Imaging, 2013; 1:289-296.
Brain: Normal Variations and Benign Findings in FDG PET/CT imaging.
PET Clinics. 2014 Apr;9(2):129-40.
Fetal striatal grafting slows motor and cognitive decline of Huntington's disease.
J Neurol Neurosurg Psychiatry. 2013 Dec 17. doi: 10.1136/jnnp-2013-306533.
Human Striatum Remodelling after Neurotransplantation in Huntington's Disease.
Stereotact Funct Neurosurg. 2014 Jul 30;92(4):211-217.
Sorbi F, Prosperi P, Villanucci A, Berti V, Sisti G, Fambrini M.
Gynecol Obstet Invest. 2015;80(4):265-71.
Berti V, Murray J, Davies M, Spector N, Tsui WH, Li Y, Williams S, Pirraglia E, Vallabhajosula S, McHugh P, Pupi A, de Leon MJ, Mosconi L.
J Nutr Health Aging. 2015 Apr;19(4):413-23. doi: 10.1007/s12603-014-0534-0.
Berti V, Polito C, Lombardi G, Ferrari C, Sorbi S, Pupi A.
Neurol Sci. 2016 May;37(5):663-72.
Berti V, Sciagrà R, Neglia D, Pietilä M, Scholte AJ, Nekolla S, Rouzet F, Pupi A, Knuuti J.
Eur J Nucl Med Mol Imaging. 2016 Jul;43(8):1522-9.
Vanzi E, Berti V, Polito C, Freddi I, Comis G, Rubello D, Sorbi S, Pupi A.
Nucl Med Commun. 2016 Apr 7. [Epub ahead of print]
Castagnoli H, Ferrantini C, Coppini R, Passeri A, Baldini K, Berti V, Cecchi F, Olivotto I, Sciagrà R.
Eur J Nucl Med Mol Imaging. 2016 Dec;43(13):2413-2422.
Lombardi G, Berti V, Tedde A, Bagnoli S, Piaceri I, Polito C, Lucidi G, Ferrari C, Ginestroni A, Moretti M, Pupi A, Nacmias B, Sorbi S.
J Alzheimers Dis. 2017 Mar 10. doi: 10.3233/JAD-161170.
Mosconi L, Berti V, Quinn C, McHugh P, Petrongolo G, Varsavsky I, Osorio RS, Pupi A, Vallabhajosula S, Isaacson RS, de Leon MJ, Brinton RD.
Mosconi L, Berti V, Guyara-Quinn C, McHugh P, Petrongolo G, Osorio RS, Connaughty C, Pupi A, Vallabhajosula S, Isaacson RS, de Leon MJ, Swerdlow RH, Brinton RD.
PLoS One. 2017 Oct 10;12(10):e0185926. doi: 10.1371/journal.pone.0185926.
Piaceri I, Bessi V, Matà S, Polito C, Tedde A, Berti V, Bagnoli S, Braccia A, Del Mastio M, Pignone AM, Pupi A, Sorbi S, Nacmias B.
J Alzheimers Dis. 2018;61(1):41-46. doi: 10.3233/JAD-170694.
Ferrari C, Lombardi G, Polito C, Lucidi G, Bagnoli S, Piaceri I, Nacmias B, Berti V, Rizzuto D, Fratiglioni L, Sorbi S.
J Alzheimers Dis. 2018;61(2):785-791. doi: 10.3233/JAD-170665.
Calistri L, Puccini B, Berti V, Grazzini G, Nardi C, Rigacci L, Colagrande S.
Acta Haematol. 2018 Jan 26;139(2):74-76. doi: 10.1159/000485548.
Luminari S, Donati B, Casali M, Valli R, Santi R, Puccini B, Kovalchuk S, Ruffini A, Fama A, Berti V, Fragliasso V, Zanelli M, Vergoni F, Versari A, Rigacci L, Merli F, Ciarrocchi A.
Clin Cancer Res. 2020 Jan 15;26(2):373-383. doi: 10.1158/1078-0432.CCR-19-2356. Epub 2019 Oct 23.
Nardi C, Calistri L, Pietragalla M, Vignoli C, Lorini C, Berti V, Mungai F, Colagrande S.
Radiol Med. 2020 Feb;125(2):145-154. doi: 10.1007/s11547-019-01102-z.
Lombardi G, Matà S, Berti V, Padiglioni S, Ginestroni A, Piaceri I, Bagnoli S, Nacmias B, De Cristofaro MT, Pupi A, Sorbi S.
Briganti V, Cuccurullo V, Berti V, Di Stasio GD, Linguanti F, Mungai F, Mansi L.
Curr Radiopharm. 2020;13(3):166-176. doi: 10.2174/1874471013666191230143610.
Lombardi G, Pupi A, Bessi V, Polito C, Padiglioni S, Ferrari C, Lucidi G, Berti V, De Cristofaro MT, Piaceri I, Bagnoli S, Nacmias B, Sorbi S.
J Alzheimers Dis. 2020;77(1):203-217. doi: 10.3233/JAD-200119.
Staderini M, Mannelli L, Antonioli E, Puccini B, Berti V, Mungai F, Vergoni F, Carrai V, Rigacci L, Bosi A.
Case Rep Hematol. 2020 Jan 16;2020:6309736. doi: 10.1155/2020/6309736.
Danti G, Berti V, Abenavoli E, Briganti V, Linguanti F, Mungai F, Pradella S, Miele V.
Radiol Med. 2020 Aug;125(8):715-729. doi: 10.1007/s11547-020-01172-4.
Lavacchi D, Antonuzzo L, Briganti V, Berti V, Abenavoli EM, Linguanti F, Messerini L, Giaccone G.
Anticancer Drugs. 2020 Jul;31(6):646-651. doi: 10.1097/CAD.0000000000000900.
Mazzeo S, Polito C, Padiglioni S, Berti V, Bagnoli S, Lombardi G, Piaceri I, Carraro M, De Cristofaro MT, Passeri A, Ferrari C, Nacmias B, Sorbi S, Bessi V.
Neurobiol Aging. 2020 Dec;96:155-164. doi: 10.1016/j.neurobiolaging.2020.09.004. Epub 2020 Sep 8.
Catricalà E, Polito C, Presotto L, Esposito V, Sala A, Conca F, Gasparri C, Berti V, Filippi M, Pupi A, Sorbi S, Iannaccone S, Magnani G, Cappa SF, Perani D.
Caminiti SP, Sala A, Presotto L, Chincarini A, Sestini S, Perani D; Alzheimer’s Disease Neuroimaging Initiative (ADNI), for the Associazione Italiana Medicina Nucleare (AIMN) datasets, The AIMN Neurology Study-Group collaborators:, Schillaci O, Berti V, Calcagni ML, Cistaro A, Morbelli S, Nobili F, Pappatà S, Volterrani D, Gobbo CL.
Eur J Nucl Med Mol Imaging. 2021 Jan 10. doi: 10.1007/s00259-020-05175-1.
Giacomucci G, Mazzeo S, Bagnoli S, Casini M, Padiglioni S, Polito C, Berti V, Balestrini J, Ferrari C, Lombardi G, Ingannato A, Sorbi S, Nacmias B, Bessi V.
J Pers Med. 2021 Jan 14;11(1):47. doi: 10.3390/jpm11010047
Tutino F, Puccini G, Linguanti F, Puccini B, Rigacci L, Kovalchuk S, Sciagrà R, Berti V.
Nucl Med Commun. 2021 Mar 1;42(3):284-291. doi: 10.1097/MNM.0000000000001324.
Cappelletto P, Polito C, Berti V, Lombardi G, Lucidi G, Bessi V, Sorbi S, Ferrari C.
Mosconi L, Berti V, Dyke J, Schelbaum E, Jett S, Loughlin L, Jang G, Rahman A, Hristov H, Pahlajani S, Andrews R, Matthews D, Etingin O, Ganzer C, de Leon M, Isaacson R, Brinton RD.
Sci Rep. 2021 Jun 9;11(1):10867. doi: 10.1038/s41598-021-90084-y.
PMID: 34108509
Mungai F, Verrone GB, Bonasera L, Bicci E, Pietragalla M, Nardi C, Berti V, Mazzoni LN, Miele V.
Radiol Med. 2021 Oct;126(10):1345-1355. doi: 10.1007/s11547-021-01376-2. Epub 2021 Jun 28.
PMID: 34181206
Allocca M, Linguanti F, Calcagni ML, Cistaro A, Gaudieri V, Guerra UP, Morbelli S, Nobili F, Pappatà S, Sestini S, Volterrani D, Berti V, For The Neurology Study Group Of The Italian Association Of Nuclear Medicine.
J Clin Med. 2021 Oct 25;10(21):4932. doi: 10.3390/jcm10214932.
PMID: 34768454
Nerattini M, Rubino F, Arnone A, Polito C, Mazzeo S, Lombardi G, Puccini G, Nacmias B, De Cristofaro MT, Sorbi S, Pupi A, Sciagrà R, Bessi V, Berti V.
Neurol Sci. 2022 Apr;43(4):2469-2480. doi: 10.1007/s10072-021-05704-2. Epub 2021 Nov 5.
PMID: 34739618
Danti G, Flammia F, Matteuzzi B, Cozzi D, Berti V, Grazzini G, Pradella S, Recchia L, Brunese L, Miele V.
Radiol Med. 2021 Dec;126(12):1497-1507. doi: 10.1007/s11547-021-01408-x. Epub 2021 Aug 24.
PMID: 34427861
Linguanti F, Abenavoli EM, Briganti V, Danti G, Lavacchi D, Matteini M, Vaggelli L, Novelli L, Grosso AM, Mungai F, Mini E, Antonuzzo L, Miele V, Sciagrà R, Berti V.
Ann Nucl Med. 2023 Jan;37(1):1-9. doi: 10.1007/s12149-022-01797-7.
J Pers Med. 2023 Jan 25;13(2):208. doi: 10.3390/jpm13020208.
Mosconi L, Jett S, Nerattini M, Andy C, Yepez CB, Zarate C, Carlton C, Kodancha V, Schelbaum E, Williams S, Pahlajani S, Loeb-Zeitlin S, Havryliuk Y, Andrews R, Pupi A, Ballon D, Kelly J, Osborne J, Nehmeh S, Fink M, Berti V, Matthews D, Dyke J, Brinton RD.
Res Sq. 2023 Feb 27:rs.3.rs-2573335. doi: 10.21203/rs.3.rs-2573335/v1. Preprint.
PMID: 36909660
Cornacchini S, Farina A, Contento M, Berti V, Biggi M, Barilaro A, Massacesi L, Damato V, Rosati E.
Front Neurol. 2022 Aug 16;13:949240. doi: 10.3389/fneur.2022.949240. eCollection 2022.
PMID: 36051221
Giacomucci G, Mazzeo S, Bagnoli S, Ingannato A, Leccese D, Berti V, Padiglioni S, Galdo G, Ferrari C, Sorbi S, Bessi V, Nacmias B.
J Neurol. 2022 Aug;269(8):4270-4280. doi: 10.1007/s00415-022-11055-5. Epub 2022 Mar 14.
PMID: 35288777
Arnone A, Allocca M, Di Dato R, Puccini G, Laghai I, Rubino F, Nerattini M, Ramat S, Lombardi G, Ferrari C, Bessi V, Sorbi S, De Cristofaro MT, Polito C, Berti V.
Neurol Sci. 2022 Sep;43(9):5333-5341. doi: 10.1007/s10072-022-06166-w. Epub 2022 Jun 14.
PMID: 35697965
Lombardi G, Lombardi N, Bettiol A, Crescioli G, Ferrari C, Lucidi G, Polito C, Berti V, Bessi V, Bagnoli S, Nacmias B, Vannacci A, Sorbi S.
Eur J Clin Pharmacol. 2022 Jul;78(7):1155-1163. doi: 10.1007/s00228-022-03325-y. Epub 2022 Apr 28.
PMID: 35484251
Abenavoli EM, Barbetti M, Linguanti F, Mungai F, Nassi L, Puccini B, Romano I, Sordi B, Santi R, Passeri A, Sciagrà R, Talamonti C, Cistaro A, Vannucchi AM, Berti V.
Cancers (Basel). 2023 Mar 23;15(7):1931. doi: 10.3390/cancers15071931.
PMID: 37046592
Giacomucci G, Galdo G, Polito C, Berti V, Padiglioni S, Mazzeo S, Chiaro E, De Cristofaro MT, Bagnoli S, Nacmias B, Sorbi S, Bessi V.
Behav Brain Res. 2022 Jun 25;428:113893. doi: 10.1016/j.bbr.2022.113893. Epub 2022 Apr 14.
PMID: 35429513
Catricalà E, Santi GC, Polito C, Conca F, Esposito V, Caminiti SP, Boccalini C, Berti V, Bessi V, Marcone A, Iannaccone S, Sorbi S, Perani D, Cappa SF.
Neurobiol Aging. 2022 Dec;120:137-148. doi: 10.1016/j.neurobiolaging.2022.09.001. Epub 2022 Sep 8.
PMID: 36195042
Mazzeo S, Polito C, Lassi M, Bagnoli S, Mattei M, Padiglioni S, Berti V, Lombardi G, Giacomucci G, De Cristofaro MT, Passeri A, Ferrari C, Nacmias B, Mazzoni A, Sorbi S, Bessi V.
Neurobiol Aging. 2022 Sep;117:59-70. doi: 10.1016/j.neurobiolaging.2022.05.002. Epub 2022 May 13.
PMID: 35665686
Boccalini C, Carli G, Tondo G, Polito C, Catricalà E, Berti V, Bessi V, Sorbi S, Iannaccone S, Esposito V, Cappa SF, Perani D.
PMID: 35717768
Mannelli F, Gesullo F, Mannarelli C, Vanderwert F, Lazzi S, Mungai F, Berti V, Santi R, Guglielmelli P, Vannucchi AM.
Am J Hematol. 2023 Mar;98(3):529-532. doi: 10.1002/ajh.26804. Epub 2022 Dec 20.
PMID: 36464921
Linguanti F, Abenavoli EM, Berti V, Lopci E.
Cancers (Basel). 2022 Sep 27;14(19):4700. doi: 10.3390/cancers14194700.
PMID: 36230629
Nuclear medicine instrumentation and image reconstruction
Neurosciences and Nuclear medicine in neurology (degenerative diseases, Parkinson’s disease, Alzheimer’s disease, Huntington’s disease), quantitative analysis (Patlak and Logan plot)Nuclear Cardiology, Nuclear Oncology, Nuclear endocrinologyExperience with amyloid tracers at New York University School of Medicine.
Experience with amyloid tracers labeled with 18F